{"product_id":"uscap-2020-annual-meeting-long-course-major-advances-in-the-diagnosis-and-management-of-breast-disease","title":"USCAP 2020 Annual Meeting Long Course – Major Advances in the Diagnosis and Management of Breast Disease","description":"\u003cdiv class=\"prod-edition\"\u003e\n\u003ch1 class=\"product-title product_title entry-title\"\u003eUSCAP 2020 Annual Meeting Long Course – Major Advances in the Diagnosis and Management of Breast Disease\u003c\/h1\u003e\n\u003cp\u003e\u003cstrong\u003eCourse Description\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"single-main-content\"\u003e\n\u003cdiv\u003e\n\u003cdiv class=\"outer-wrapper\"\u003e\n\u003csection class=\"content\"\u003e\n\u003cdiv class=\"description\" data-role=\"course-description\"\u003e\n\u003cp\u003eDiagnostic breast pathology has become increasingly complex with the recognition of novel molecular subtypes of breast cancer dictating differing therapeutic strategies; the prospect of de-escalation of therapy in patients with ductal carcinoma in situ; the expansion of morphologic patterns of lobular carcinoma in situ; the ongoing challenge of accurate categorization of papillary and fibroepithelial lesions; the move toward fewer surgical excisions following diagnoses of benign and atypical lesions on core needle biopsy and the panoply of immunohistochemical stains and ancillary molecular tests available to corroborate diagnoses and guide neoadjuvant and adjuvant therapy\u003c\/p\u003e\n\u003cp\u003eThe purpose of this course is to provide practicing pathologists with an updated framework for diagnosing breast lesions, both commonly and less commonly encountered in daily practice. Some of the top experts in the field will present their approach to these challenges, as well as provide information on the latest guideline recommendations and management strategies.\u003c\/p\u003e\n\u003cdetails open=\"open\"\u003e\n\u003csummary\u003e\u003cstrong\u003eTarget Audience\u003c\/strong\u003e\u003c\/summary\u003e\n\u003cp\u003ePracticing academic and community pathologists, and pathologists-in-training\u003c\/p\u003e\n\u003c\/details\u003e\n\u003cdetails open=\"open\"\u003e\n\u003csummary\u003e\u003cstrong\u003eLearning Objectives\u003c\/strong\u003e\u003c\/summary\u003e\n\u003cp\u003eUpon completion of this educational activity, learners will be able to:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eUpdate current knowledge on recent advances in diagnostic breast pathology\u003c\/li\u003e\n\u003cli\u003eRecognize the ramifications of pathologic diagnoses in light of evolving management strategies\u003c\/li\u003e\n\u003cli\u003eUnderstand the molecular underpinnings of breast tumors and their associated therapeutic impact\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/details\u003e\n\u003cdetails open=\"open\"\u003e\n\u003csummary\u003e\u003cstrong\u003eContinuing Medical Education and Continuing Certification\u003c\/strong\u003e\u003c\/summary\u003e\n\u003cp\u003eThe United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.\u003c\/p\u003e\n\u003cp\u003eThe United States and Canadian Academy of Pathology designates this enduring material for a maximum of 4 \u003cem\u003eAMA PRA Category 1 Credits\u003c\/em\u003e\u003csup\u003eTM\u003c\/sup\u003e. Physicians should claim only the credit commensurate with the extent of their participation in the activity.\u003c\/p\u003e\n\u003cp\u003eUSCAP is approved by the American Board of Pathology (ABPath) to offer Self-Assessment credits (SAMs) and Lifelong Learning (Part II) credit for the purpose of meeting the ABPath requirements for Continuing Certification (CC). Registrants must take and pass the post-test in order to claim SAMs credit. Physicians can earn a maximum of 4 SAM\/Part II credit hours.\u003c\/p\u003e\n\u003c\/details\u003e\n\u003cdetails open=\"open\"\u003e\n\u003csummary\u003e\u003cstrong\u003eDisclosures\u003c\/strong\u003e\u003c\/summary\u003e\n\u003cp\u003eThe faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any relevant financial relationship(s) of the individual or spouse\/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.\u003c\/p\u003e\n\u003cp\u003eThe following faculty reported relevant financial relationships: Ashley Cimino-Matthews, MD: \u003cem\u003eGrant or Research Support\u003c\/em\u003e, Bristol-Myers Squibb, \u003cem\u003eConsultant\u003c\/em\u003e, Bristol-Myers Squibb\u003c\/p\u003e\n\u003cp\u003eThe following faculty reported no relevant financial relationships: Kimberly H. Allison, MD, Sunil L. Lakhani, MD, Jorge S. Reis-Filho, MD, PhD, FRCPath, Stuart J. Schnitt, MD, Puay Hoon Tan, MBBS, FRCPA, FAMS, MD, FRCPath, MIAC\u003c\/p\u003e\n\u003cp\u003eThe following planners reported financial relationships:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAshley Cimino-Mathews: \u003cem\u003eGrant or Research Support\u003c\/em\u003e: Bristol-Myers Squibb\u003c\/li\u003e\n\u003cli\u003eYuri Fedoriw: \u003cem\u003eConsultant\u003c\/em\u003e: Alexion Pharmaceuticals\u003c\/li\u003e\n\u003cli\u003eJoel Greenson: \u003cem\u003eConsultant\u003c\/em\u003e, Genentech\/Roche\u003c\/li\u003e\n\u003cli\u003eJason Hornick:\u003cem\u003e Consultant\u003c\/em\u003e: Eli Lilly, Epizyme\u003c\/li\u003e\n\u003cli\u003eAnna Marie Mulligan: \u003cem\u003eSpeaker\u003c\/em\u003e: AstraZeneca; \u003cem\u003eConsultant\u003c\/em\u003e: Roche\u003c\/li\u003e\n\u003cli\u003eLynette Sholl: \u003cem\u003eAdvisory Board Member\u003c\/em\u003e: LOXO Oncology; \u003cem\u003eSpeaker\u003c\/em\u003e: AstraZeneca; \u003cem\u003eGrant or Research Support\u003c\/em\u003e: Roche\/Genentech\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe following planners reported no relevant financial relationships: Zubair Baloch, Steven Billings, Daniel Brat, James Cook, Sarah Dry, William Faquin, Karen Fritchie, L. Priya Kunju, Laura Lamps, Rish Pai, David Papke, Jr., Vinita Parkash, Carlos Parra-Herran, Anil Parwani, Rajiv Patel, Deepa Patil, Raja Seethala, Ilan Weinreb, Rhonda Yantiss, Nicholas Zoumberos.\u003c\/p\u003e\n\u003cp\u003eUSCAP staff associated with the development of content for this activity reported no relevant financial relationships.\u003c\/p\u003e\n\u003c\/details\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch3\u003e\u003cstrong\u003eTopics\/Speaker:\u003cbr\u003e\n\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eContemporary Criteria for Diagnosis of LCIS and the Molecular Correlates\u003c\/li\u003e\n\u003cli\u003eDiagnosis of DCIS in an Era of De-escalation of Therapy\u003c\/li\u003e\n\u003cli\u003eFibroepithelial Lesions Revisited; Implications for Diagnosis and Management\u003c\/li\u003e\n\u003cli\u003eNovel Uses of IHC in Breast Pathology, Interpretation and Pitfalls\u003c\/li\u003e\n\u003cli\u003ePrecision Pathology as Applied to Breast Core Needle Biopsy Evaluation Implications for Management\u003c\/li\u003e\n\u003cli\u003eProblematic Breast Tumors Reassessed in Light of Novel Molecular Data\u003c\/li\u003e\n\u003cli\u003ePrognostic and Predictive Parameters in Breast Cancer\u003c\/li\u003e\n\u003cli\u003eThe Never-Ending Saga of Papillary Lesions of the Breast\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOriginal release date: April 21, 2020\u003c\/strong\u003e\u003cbr\u003e\n\u003cstrong\u003eAccess to this course expires on:\u003c\/strong\u003e  \u003cstrong\u003eMarch 4, 2023\u003c\/strong\u003e at 11:59 PM Pacific Time\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n","brand":"My Store","offers":[{"title":"Default Title","offer_id":42954657431650,"sku":"MED-AMB07674","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/2020-Annual-Meeting-Long-Course-Major-Advances-in-the-Diagnosis-and-Management-of-Breast-Diseases.jpg?v=1779381810","url":"https:\/\/meducourse.com\/products\/uscap-2020-annual-meeting-long-course-major-advances-in-the-diagnosis-and-management-of-breast-disease","provider":"Meducourse","version":"1.0","type":"link"}